Suppr超能文献

体外产生针对T细胞上同种异体抗原特异性识别位点以及淋巴细胞毒性HLA抗体的抗体。

Production in vitro of antibodies directed against alloantigen-specific recognition sites on T cells and on lymphocytotoxic HLA antibodies.

作者信息

Singal D P, Blajchman M A, Joseph S, Roberge B, Smith E K, Ludwin D

机构信息

Department of Pathology, McMaster University, Hamilton, Ontario, Canada.

出版信息

Clin Exp Immunol. 1988 May;72(2):222-7.

Abstract

We have examined the mechanism of immunological unresponsiveness in a recipient (P.S.) with a long-term functioning renal allograft. P.S., whose HLA type is A1, A30; B14, B18; DR1, w8; DRw52; DQw1 and in whose serum we had earlier demonstrated the presence of antiidiotypic antibodies, received a kidney from a cadaver donor of HLA type A1, A10, B8 in March, 1970. Peripheral blood B lymphocytes from the patient were transformed with Epstein-Barr virus (EBV), and by the cluster-picking technique a B cell line was propagated with continuous production of antibodies. Antiidiotypic antibodies with two distinct biological functions were demonstrable; one specifically inhibiting the lymphocytotoxic activity of anti-HLA-B8, B5, and DR3 reference typing sera, and the other specifically inhibiting proliferative responses in MLC of the recipient's lymphocytes and of third party cells sharing B14, DR1, DQw1 with the patient against stimulator cells carrying B8, DR3 antigens. Immunodepletion experiments demonstrated that the inhibitory activity was associated with the IgM fraction. Absorption experiments suggested that different antibodies may be responsible for the inhibition of lymphocytotoxic activity of anti-HLA sera and of the proliferative responses in MLC. Antiidiotypic antibodies have been postulated to be important in maintaining allograft tolerance in vivo, thereby enhancing renal allograft survival. The availability of such antibodies in large quantities, produced in vitro, could provide antisera for the immunochemical characterization of specific idiotypic receptors on immunoglobulins and T lymphocytes.

摘要

我们研究了一名长期存活的肾移植受者(P.S.)免疫无反应性的机制。P.S.的HLA型别为A1、A30;B14、B18;DR1、w8;DRw52;DQw1,我们先前已在其血清中证实存在抗独特型抗体。1970年3月,P.S.接受了一名HLA型别为A1、A10、B8的尸体供者的肾脏。患者的外周血B淋巴细胞用爱泼斯坦 - 巴尔病毒(EBV)进行转化,通过集落挑选技术培养出一个B细胞系,并持续产生抗体。可证明有两种具有不同生物学功能的抗独特型抗体;一种特异性抑制抗HLA - B8、B5和DR3参考分型血清的淋巴细胞毒性活性,另一种特异性抑制受者淋巴细胞以及与患者共有的B14、DR1、DQw1的第三方细胞在混合淋巴细胞培养(MLC)中对携带B8、DR3抗原的刺激细胞的增殖反应。免疫去除实验表明抑制活性与IgM部分相关。吸收实验提示不同抗体可能分别负责抑制抗HLA血清的淋巴细胞毒性活性和MLC中的增殖反应。抗独特型抗体被认为在体内维持移植耐受从而提高肾移植存活率方面很重要。体外大量产生的此类抗体可用于提供抗血清,以对免疫球蛋白和T淋巴细胞上的特异性独特型受体进行免疫化学鉴定。

相似文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验